Follicular Lymphoma Trials
Explore how clinical research is advancing treatment and discover studies that may be a match for your diagnosis and treatment history.
What are Follicular Lymphoma trials?
Clinical trials are research studies involving people, designed to evaluate new treatments, drugs, procedures, or interventions tor safety, effectiveness, and potential advantages over current options.
Follicular lymphoma clinical trials are research studies testing new therapies such as CAR-T cell therapy, bispecific antibodies, monoclonal antibodies, targeted treatments, and innovative immune-based combinations.
Participation in a clinical trial often means contributing to progress in medicine while potentially gaining early access to innovative care.
CancerBot helps patients and clinicians find clinical trials they are actually eligible for by analyzing structured eligibility criteria and matching them to real patient data. Instead of searching through hundreds of listings, you receive personalized matches in minutes.
Understanding Follicular Lymphoma
Follicular Lymphoma is a slow-growing type of non-Hodgkin lymphoma that originates in the lymphatic system, which is part of the body's immune defense.
It affects B-cells, a type of white blood cell responsible for producing antibodies. Follicular Lymphoma is typically indolent, meaning it progresses gradually over time.
While it is often considered incurable, many patients live for years with effective management. Clinical trials continue to explore new therapies to extend remission times and improve quality of life.
Treatment options
Treatment for Follicular Lymphoma depends on the stage of the disease, symptoms, and the patient's overall health. Common treatments include:
Watchful waiting (active surveillance for patients without symptoms)
Monoclonal antibody therapy (e.g., rituximab)
Combination chemotherapy (e.g., R-CHOP, R-CVP)
Targeted therapy (e.g., PI3K inhibitors)
Radiotherapy for localized disease
CAR-T therapy (in specific cases)
Immunitherapy
Clinical trials often provide access to newer treatments not yet standard of care.
How diagnosis works
Diagnosing Follicular Lymphoma involves:
Physical examination to check for swollen lymph nodes, often in the neck, armpits, or groin.
Blood tests to assess overall health and identify any abnormalities that could suggest lymphoma.
Imaging tests, such as CT scans or PET scans, used to locate enlarged lymph nodes or other signs of disease throughout the body.
Lymph node biopsy For definitive diagnosis, where a sample of an affected lymph node is removed and examined under a microscope to confirm the presence of cancerous B-cells.
Bone marrow biopsy might be recommended in some cases, to determine if the lymphoma has spread.
Accurate diagnosis is crucial to staging the disease and choosing the most effective treatment plan.
Survival for Follicular Lymphoma
Follicular Lymphoma generally has a favorable outlook compared to more aggressive lymphomas.
The 5-year survival rate is around 90%, but the disease often recurs after treatment.
Many patients experience multiple remissions and relapses throughout their lifetime. Participation in clinical trials can offer access to novel therapies aimed at prolonging remission and minimizing side effects.
Outcomes vary based on factors such as age, stage at diagnosis, overall health, and response to treatment.
Follicular Lymphoma clinical trials available now
Current studies focus on early-stage disease, metastatic cancer, HER2-positive tumors, TNBC, and hormone-driven cancers. Trials may involve targeted therapy, Current follicular lymphoma trials are evaluating:
CAR-T cell therapies
Bispecific antibodies
Antibody-drug conjugates
Next-generation targeted treatments
Combination regimens for newly diagnosed patients
Novel approaches for relapsed or refractory disease
Some studies focus on newly diagnosed patients, while others are designed for relapsed or refractory disease. Because eligibility often depends on prior treatments, disease stage, and measurable disease status, finding the right trial can be complex.
Precision matching improves the likelihood of finding appropriate studies. CancerBot helps patients and clinicians find follicular lymphoma clinical trials they are truly eligible for by analyzing structured eligibility criteria and matching them to real patient data., cancer vaccines, or new drug combinations. Eligibility varies, which is why personalized matching is essential.
Blog
Related research and insights
Start your Al-powered clinical trial search
New treatment options could be just a click away. Start a chat with CancerBot matched with clinical trials tailored to you-quickly, easily, and at no cost.
Frequently asked questions
Everything else you need to know.
Are CAR-T therapies available through clinical trials?
Yes. Many current studies evaluate CAR-T cell therapy and other advanced immunotherapies for follicular lymphoma.
Are trials only for advanced or relapsed disease?
No. Some trials focus on early-stage or indolent lymphoma, while others are designed for relapsed or refractory disease.
Who qualifies for follicular lymphoma trials?
Eligibility depends on stage, prior treatments, measurable disease, lab values, and overall health. Each study defines its own inclusion and exclusion criteria.
Does it cost money to join a clinical trial?
Trial drugs and study procedures are usually free. Standard care is billed normally.